Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Inclusion Criteria10

• Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor chimerism is below 98% without concurrent hematologic relapse (that is, patients with \<5% bone marrow blasts as obtained at that time point) will be offered treatment with azacitidine
• \>=30 -180 days post SCT and patients must have ANC\> 1000, PLT \> 50,000
• Age 18-75 years old
• Performance score of at least 70% by Karnofsky
• Adequate kidney and liver function as demonstrated by:
• Creatinine clearance should be \>60 ml/min
• Total Bilirubin \<1.5, ALT/AST/Alk Phos \< 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.
• Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.
• Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.
• Patients must be off any prior chemotherapy, radiotherapy, or other investigational therapy within 2 weeks prior to start treatment